Uncovering a Hidden Mechanism in Met Receptor Activation

Why It Matters

Clarifying Met activation offers new targets for cancer and regenerative‑medicine therapies, while the combined cross‑linking/HS‑AFM workflow expands the toolkit for native‑state structural biology.

Key Takeaways

• HGF triggers Met dimerization via IPT4 domain.
• HS‑AFM visualized full‑length Met dimer in cells.
• 2:2 HGF‑Met complex forms peripheral HGF binding.
• In‑cell cross‑linking enables native‑state structural analysis.
• Findings may guide targeted Met inhibitors for oncology.

Pulse Analysis

The Met receptor, a central conduit for hepatocyte growth factor signaling, orchestrates tissue repair, morphogenesis, and tumor metastasis. Traditional structural techniques have captured only truncated ectodomains, leaving the architecture of the full‑length, membrane‑embedded dimer ambiguous. By demonstrating that HGF binding at the distal Sema region simultaneously induces proximity of the IPT4 domains, the new work resolves a long‑standing gap in our mechanistic understanding and highlights a dual‑site activation model that could be exploited for therapeutic modulation.

A standout feature of the research is its methodological innovation. The team chemically cross‑linked Met dimers within living cells, preserving native conformations before extraction. High‑speed atomic force microscopy then imaged these complexes at nanometer resolution, while split‑luciferase complementation confirmed ectodomain proximity. Complementary cryo‑EM of reconstituted ectodomains and extensive molecular‑dynamics simulations refined the structural model, illustrating how peripheral HGF molecules anchor the dimer and stabilize IPT4 interactions. This multi‑modal pipeline overcomes the limitations of static, in‑vitro structures and sets a precedent for studying other transient, membrane‑bound assemblies.

From a translational perspective, the clarified activation pathway opens avenues for designing inhibitors that disrupt the IPT4 interface, potentially yielding more selective anti‑Met agents with fewer off‑target effects. Moreover, the cross‑linking/HS‑AFM strategy can be generalized to interrogate a broad spectrum of growth‑factor receptors, cytokine complexes, and other signaling hubs that elude conventional crystallography or cryo‑EM. As precision oncology and regenerative medicine increasingly rely on nuanced receptor biology, such high‑resolution, physiologically relevant insights become indispensable for next‑generation drug discovery.